跳至主要内容
临床试验/NCT00688623
NCT00688623已完成2 期

A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 73 人开始时间: 2009年6月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
73
试验地点
1
主要终点
Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP)

研究概览

简要总结

To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Everolimus

Experimental

Everolimus

干预措施: Everolimus (Drug)

结局指标

主要结局

Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP)

时间窗: baseline up to approximately 12 months

Overall response rate (ORR) was based on RECIST central assessment and defined as the percentage of patients with best overall response (BOR) of a confirmed complete response (CR) or partial response (PR). The BOR was calculated on basis of the tumor of overall lesion response evaluated at each visit. To be assigned a status of PR or CR, changes in tumor measurements had to be confirmed by repeat assessments obtained within 4 weeks after the criteria for response were first met. Assessments was based on RECIST criteria 1.0. Measurable disease lesions had to be accurately measured in at least one dimension with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan (with minimum lesion size no less than double the slice thickness). PR required at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. CR required disappearance of all target and non-target lesions.

Percentage of Participants With Objective Response Rate at 12 Months - Per Protocol Set (PP)

时间窗: baseline up to approximately 12 months

Overall Response Rate (ORR) was calculated for total PP population based on central review as confirmatory, primary analysis as well as for ITT population as sensitivity analysis. It was presented with relative frequencies and the exact 2-sided 80% confidence limit (CI) computed using the Clopper-Pearson method). If the lower limit of the CI did not include p0=5%, the hypothesis that p ≤ 5% was rejected. The primary analysis was based on the PP Set

Percentage of Participants With a Overall Response Rate With a Complete Response (CR) or Partial Response (PR) at 12 Months ITT Set

时间窗: baseline up to approximately 12 months

The best overall response (BOR) was calculated on basis of the tumor of overall lesion response evaluated at each visit. To be assigned a status of PR or CR, changes in tumor measurements had to be confirmed by repeat assessments that should have been performed not less than 4 weeks after the criteria for response were first met. Assessments was based on RECIST criteria 1.0. Measurable disease lesions had to be accurately measured in at least one dimension with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan (with minimum lesion size no less than double the slice thickness). PR required at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. CR required disappearance of all target and non-target lesions.

Percentage of Participants With Objective Response Rate at 12 Months ITT Set

时间窗: baseline up to approximately 12 months

Overall Response Rate (ORR) was presented for ITT population as sensitivity analysis. It was presented with relative frequencies and the exact 2-sided 80% confidence limit (CL; computed using the Clopper-Pearson method). If the lower limit of the CI did not include p0=5%, the hypothesis that p ≤ 5% was rejected.

次要结局

  • Percentage of Participants With Disease Control Rate (DCR) at 12 Months for Per Protocol (PP) and ITT Sets(baseline up to approximately 12 months)
  • Percentage of Participants' Biochemical Response Rate Based on the Tumor Marker Chromogranin A (CgA)(baseline up to approximately 12 months)
  • Duration of Progression Free Survival (PFS) for Per Protocol (PP) and ITT Sets(baseline up to approximately 12 months)
  • Overall Survival (OS) for Per Protocol (PP) and ITT Sets(baseline up to approximately 15 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
2 期
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in EuropeCarcinomaRenal CellNon Clear Cell Renal CarcinomaPapillary Cell Renal CarcinomaAdenocarcinoma
NCT00688753Novartis Pharmaceuticals92
已完成
3 期
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)Advanced Gastric Cancer
NCT00879333Novartis Pharmaceuticals656
进行中(未招募)
不适用
A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer - RAPTORPatients who have metastatic papillary cancer of the kidney and have not received prior systemic treatment for their metastatic RCC. This multicenter international trial will enroll a maximum of 60 patients over a period of approximately 12 months.MedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinoma
EUCTR2008-006181-28-FRovartis Pharma Services AG60
进行中(未招募)
不适用
A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancerPatients who have metastatic papillary cancer of the kidney and have not received prior systemic treatment for their metastatic RCC. This multicenter international trial will enroll a maximum of 60 patients over a period of approximately 12 months.MedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinoma
EUCTR2008-006181-28-BEovartis Pharma Services AG55
进行中(未招募)
不适用
A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer - RAPTOR
EUCTR2008-006181-28-DEovartis Pharma Services AG55
RAMSETE: RAD001 in Advanced and Metastatic Silent... | 临床试验